monoclonal antibody (c6D8)

Catalog #: 0201-021

Lot #: 1401002

Immunogen: Venezuelan equine encephalitis virus replicons encoding Zaire ebolavirus (ZEBOV) glycoprotein (GP) was used to generate the original mouse monoclonal antibody.

Description: A murine / human chimeric IgG produced in *N. benthamiana* and is reactive to ZEBOV GP. The antibody detects GP in virus-like particles (VLP) and recombinant GP without the transmembrane region (rGPdTM).

Supplied: 100 µg is supplied at a concentration of 3.85 mg/mL. No preservative is added.

Purification: Antibody is purified using immobilized protein A.

 $\begin{tabular}{ll} \textbf{Clonality:} & \textbf{Murine variable, human constant of the } \textbf{IgG1} \\ & \textbf{isotype.} \end{tabular}$

Relevance: The antibody can be used for detection of ZEBOV GP. A mixture of all three anti-ZEBOV GP chimeric antibodies was protective against lethal challenge in a nonhuman primate study (Olinger *et al.* PNAS 2012, vol. 109, no. 44, 18030-18035).

Recommended Dilutions:

ELISA: Assay-dependent dilution

WB: Assay-dependent dilution. Internal QC demonstrates good detection when using antibody at $0.5 \mu g/mL$.

Storage: 2-3 weeks +4°C, -20°C long term


Cross Reactivity: No cross-reactivity was observed to Sudan ebolavirus (SEBOV) or Marburg Virus (MARV) VLP or rGPdTM.

Related Products:

IBT provides a wide array of anti-filovirus specific antibodies, recombinant proteins and other infectious disease reagents. Please see our website, <u>www.ibtbioservices.com</u> for more details.

21 Firstfield RD * Suite 100 Gaithersburg, MD 20878 877-411-2041 Services@ibtbioservices.com

Western Blot Data:



Western blots were detected under reduced conditions with anti-ZEBOV GP chimeric antibody at 0.5 μ g/mL and visualized using an anti-human IgG-HRP conjugate and TMB membrane substrate. GP is visualized in Baculovirus expressed ZEBOV VLP (lane 1) but not in the SEBOV or MARV VLP (lanes 2, 3). ZEBOV rGPdTM expressed in insect cells is also visualized (lane 4).

ELISA Data:

	OD 650	
Antibody	ZEBOV VLP	ZEBOV rGPdTM
(μg/mL)	@ 10 μg/mL	@ 1 μg/mL
2.0000	2.6520	3.6990
0.6325	2.5220	3.6840
0.2000	2.1130	3.7220
0.0632	0.9990	3.6670
0.0200	0.4740	2.8740
0.0063	0.2670	1.5370
0.0020	0.1440	0.6220
0.0006	0.0920	0.2440
0.0002	0.0590	0.1100
0.0000	0.0547	0.0528

VLPs were solubilized in a final concentration of 1% Triton X-100 and diluted to $10~\mu g/mL$ in PBS (0.01% Triton) for plate coating. rGPdTM proteins were diluted to $1~\mu g/mL$ in PBS. Anti-ZEBOV GP chimeric antibody was serially diluted semi-log from $2~\mu g/mL$ and incubated on the coated plates. Washed plates were detected with anti-human IgG-HRP conjugate and TMB substrate. OD_{650} is reported above.

Additional testing results:

Test Method	Result
Endotoxin	0.12 EU/mg
Bioburden	0 CFU/mL
Size Exclusion HPLC	91.1% monomer
	1.4% High Molecular Weight
	7.5% Low Molecular Weight
Residual Host Cell DNA	0.45 ng/mg
Residual Host Cell Protein	Below limit of detection
	(3.125 ng/mL)

Intended for research use only, not for human, therapeutic, or diagnostic applications.

The buyer cannot sell or otherwise transfer this product for Commercial Purposes without written approval of Integrated BioTherapeutics, Inc.